Matthew Davidson was named President and Chief Executive Officer of Azora Therapeutics, Inc. (DE). As of November 10, 2026, Azora Therapeutics, Inc. (DE) has reported 4 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 11, 2026 to November 9, 2026, naming 5 appointments and 1 departure (Form 8-K, October 28, 2026).
Azora Therapeutics, Inc. (DE) named a new Director on Nov 9. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Azora Therapeutics, Inc. (DE)? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Aida Habtezion · Role: Director · 8-K, 2026-11-09
- · In / out: In · Person: Matthew Davidson · Role: President and Chief Executive Officer · 8-K, 2026-10-28
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-13
- · In / out: Out · Person: Tony Goodman · 8-K, 2026-06-11
Azora Therapeutics, Inc. (DE) reported changes in 4 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-11 to 2026-11-09. They name 6 people, with 5 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Azora Therapeutics, Inc. (DE) files it.
Also on the record for Azora Therapeutics, Inc. (DE)
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Stake report, Schedule 13G/A, by Coastlands Capital LP | 4.99% of the class | 5%+ stakes | Source |
| July 1, 2026 | Stake report, Schedule 13G/A, by Coastlands Capital LP | 14.22% of the class | 5%+ stakes | Source |
| June 24, 2026 | Stake report, Schedule 13G, by Coastlands Capital LP | 9.98% of the class | 5%+ stakes | Source |
| June 11, 2026 | Acquired Azora Therapeutics, Inc. | $26.80M | Acquisition | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| February 18, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
| December 3, 2025 | Form D, private offering | $4.29M sold | Form D page | Source |
| May 14, 2025 | Form D, private offering | $4.82M sold | Form D page | Source |
Selling to them or working with them? See who runs Azora Therapeutics, Inc. (DE) now and the warning signs.
Free to see. No signup.
Keep reading
More on Azora Therapeutics, Inc. (DE) and the records around it.
Azora Therapeutics, Inc. (DE) elsewhere on the record
- Acquisition Jun 2026
- Form D filing Dec 2025
- Form D filing May 2025
- Who owns it
Companies that share a holder
- Coastlands Capital LP also filed stake reports on 15 other companies: Bolt Biotherapeutics, Inc. (Nov 2026), Kalaris Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Azora Therapeutics, Inc. (DE)
Get an email when Azora Therapeutics, Inc. (DE) files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Azora Therapeutics, Inc. (DE)?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Azora Therapeutics, Inc. (DE): verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Azora Therapeutics, Inc. (DE) covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-09 | In | Director | 8-K, 2026-11-09 | ||
| 2026-10-28 | In | President and Chief Executive Officer | 8-K, 2026-10-28 | ||
| 2026-10-28 | In | Chief Financial Officer | 8-K, 2026-10-28 | ||
| 2026-10-28 | In | Chief Strategy Officer | 8-K, 2026-10-28 | ||
| 2026-08-13 | Reported | not named in the filing | 8-K, 2026-08-13 | ||
| 2026-06-11 | Out | 8-K, 2026-06-11 | |||
| 2026-06-11 | In | Chief Development Officer | 8-K, 2026-06-11 |
Who leads Azora Therapeutics, Inc. (DE), as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Aida Habtezion, appointed (filed 2026-11-09).
- Chief Strategy Officer: Julie Saiki, appointed (filed 2026-10-28).
- Chief Financial Officer: Celia Economides, appointed (filed 2026-10-28).
- President and Chief Executive Officer: Matthew Davidson, appointed (filed 2026-10-28).
- Chief Development Officer: Matt Davidson, appointed (filed 2026-06-11).
New leaders reset buying decisions — get the Full Report on Azora Therapeutics, Inc. (DE): who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Azora Therapeutics, Inc. (DE), with the record behind each one.
Find candidates like Director at Azora Therapeutics, Inc. (DE)Every change, in the filing's words
Appointed: Aida Habtezion, Director
Dr. Habtezion was appointed to the Board as a Class I director, with a term expiring at the Company's 2028 Annual Meeting of Stockholders, and Mr. Hastings and Mr. Soloway were appointed to the Board as Class II directors, each with a term expiring at the Company's 2029 Annual Meeting of Stockholders (Dr. Habtezion, Mr. Hastings and Mr. Soloway, collectively, the "New Directors").
- Appointment of New Directors On November 3, 2026, each of Aida Habtezion, M.D., Paul Hastings and Thomas Soloway were appointed to the Board of Directors (the "Board") of Azora Therapeutics, Inc. (formerly known as Adial Pharmaceuticals, Inc.) (the "Company").
- The Board has determined that each of the New Directors is independent under the listing standards of The Nasdaq Stock Market LLC ("Nasdaq").
- Aida Habtezion, M.D. is a physician-scientist in gastroenterology and immunology who served as Chief Medical Officer and Head of Worldwide Medical & Safety at Pfizer.
- She is an Adjunct Professor of Medicine and previously a tenured Professor of Medicine at Stanford University School of Medicine, where she directed a translational research laboratory studying intestinal inflammatory disease, including the role of the aryl hydrocarbon receptor in intestinal immunity.
- Paul J. Hastings is Chief Executive Officer of Nkarta.
- Living with Crohn's disease himself, he is passionate about advancing care in the inflammatory bowel disease community.
- He has led numerous biopharmaceutical companies as Chief Executive Officer, including OncoMed Pharmaceuticals, QLT, and Axys Pharmaceuticals.
- He currently serves on the boards of Specific Biologics and enGene Holdings, and was formerly the Chair of the Biotechnology Innovation Organization.
Appointed: Matthew Davidson, President and Chief Executive Officer
The Board of Directors (the " Board ") of Azora Therapeutics, Inc., formerly known as Adial Pharmaceuticals, Inc. (the " Company "), appointed Matthew Davidson, Ph.D. as President and Chief Executive Officer of the Company, on October 28, 2026 (the " Effective Date ").
Appointed: Celia Economides, Chief Financial Officer
Effective as of the Effective Date, the Board appointed Celia Economides as the Company's Chief Financial Officer.
Appointed: Julie Saiki, Chief Strategy Officer
Subject to the execution of a release, Mr. Shah will be entitled to receive the severance payments and benefits provided for by his amended and restated employment agreement, as amended by the first amendment thereto. 1 Appointment of Chief Strategy Officer Effective as of the Effective Date, the Board appointed Julie Saiki, Ph.D. as the Company's Chief Strategy Officer.
- Dr. Davidson will also remain a member of the Board.
- Matthew Davidson, Ph.D. (age 42) has served as the Company's Chief Development Officer and a member of the Board since June 2026.
- Dr. Davidson previously served as the Chief Executive Officer, Co-Founder and Chairman of the Board of Directors of Azora Therapeutics, Inc. ("Legacy Azora") since its inception in March 2019.
- From August 2013 until December 2017, he served as the Chief Executive Officer, Founder and Chairman of the Board of Directors of Verrica Pharmaceuticals, Inc., a Nasdaq-listed company, where he invented and developed the first FDA-approved drug for the skin disease molluscum contagiosum.
- Dr. Davidson holds a Ph.D. in Immunology from Stanford University School of Medicine and a B.A. in Molecular and Cell Biology from the University of California, Berkeley.
- Dr. Davidson's existing compensation arrangements with the Company remain unchanged following his appointment.
- In connection with Dr. Davidson's appointment as President and Chief Executive Officer, Dr. Davidson will succeed Cary J. Claiborne, whose employment was terminated effective as of the Effective Date.
- Subject to the execution of a release, Mr. Claiborne will be entitled to receive the severance payments and benefits provided for by his amended and restated employment agreement, as amended by the first amendment thereto.
Reported
As of August 10, 2026, Adial Pharmaceuticals, Inc. (the "Company") anticipates that the employment of its current President and Chief Executive Officer, Cary Claiborne, will be terminated effective promptly after the Company's 2026 Annual Meeting of Stockholders ("the 2026 Annual Meeting") if certain of the proposals being presented to stockholders are approved (the "Stockholder Approval"), and that Matthew Davidson, the Company's Chief Development Officer and a member of our Board of Directors, will be appointed as the Company's President and Chief Executive Office.
- Additionally, the Company anticipates that the employment of its current Chief Financial Officer, Vinay Shah, will be terminated effective promptly after the 2026 Annual Meeting if Stockholder Approval is obtained, and that a new Chief Financial Officer will be appointed.
- Upon such terminations, and subject to their respective execution of a release, Messrs. Claiborne and Shah will be entitled to receive the severance payments and benefits provided for by their amended and restated employment agreements.
Departing: Tony Goodman
Effective Time, Tony Goodman resigned as a Class I Director of the Company.
Appointed: Matt Davidson, Chief Development Officer
Mr. Goodman did not resign as a result of any disagreements with the Board or the Company. 6 Appointment of Directors and Chief Development Officer On June 11, 2026, in connection with the Merger, effective immediately after the First Effective Time, Matt Davidson, Ph.D., was appointed to the Board as a Class I Director, to fill the vacancy created by the resignation of Mr. Goodman, with a term expiring at the Company's 2028 Annual Meeting of Stockholders, and Wendy B. Young, Ph.
- - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Director Fees On June 11, 2026, upon closing of the Merger, each director of the Company immediately prior to the First Effective Time will receive cash payment of $30,000.
- D. was appointed to the Board as a Class III Director, filling a standing vacancy on the Board, with a term expiring at the Company's 2027 Annual Meeting of Stockholders.
- On June 11, 2026, effective immediately after the First Effective Time, Dr. Davidson was also appointed as the Company's Chief Development Officer.
- Dr. Davidson and Dr. Young were not appointed as a member to any Committee of the Board.
- Matt Davidson (age 42) was appointed as the Company's Chief Development Officer and member of the Board effective as of immediately after the First Effective Time.
- Prior to the Merger Closing, Dr. Davidson served as the Chief Executive Officer, Co-Founder and Chairman of the Board of Directors of Azora since its inception in March 2019.
- From August 2013 until December 2017, he served as the Chief Executive Officer, Founder and Chairman of the Board of Directors of Verrica Pharmaceuticals, Inc., a Nasdaq-listed company, where he invented and developed the first FDA-approved drug for the skin disease molluscum contagiosum.
Tools for this story
Each opens in a new tab, filled in for Azora Therapeutics, Inc. (DE). With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.